Works in Journal of Dermatological Treatment, 2022, Vol 33, Issue 3


Results: 106
    1
    2

    Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study

    Published in:
    Journal of Dermatological Treatment, 2022, v. 33, n. 3, p. 1718, doi. 10.1080/09546634.2021.1902925
    By:
    • Sigurgeirsson, Bardur;
    • Schäkel, Knut;
    • Hong, Chih-Ho;
    • Effendy, Isaak;
    • Placek, Waldemar;
    • Rich, Phoebe;
    • Keefe, Deborah;
    • Bruin, Gerard;
    • Charef, Pascal;
    • Fu, Rong;
    • Hampele, Isabelle;
    • Patekar, Manmath
    Publication type:
    Article
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43

    Dermatological trends in emergency medicine.

    Published in:
    Journal of Dermatological Treatment, 2022, v. 33, n. 3, p. 1746, doi. 10.1080/09546634.2020.1853025
    By:
    • Kody, Shannon;
    • Cline, Abigail;
    • Pereira, Frederick A.
    Publication type:
    Article
    44
    45

    Disease response and patient-reported outcomes among initiators of ixekizumab.

    Published in:
    Journal of Dermatological Treatment, 2022, v. 33, n. 3, p. 1538, doi. 10.1080/09546634.2020.1853023
    By:
    • Shahriari, Mona;
    • Harrison, Ryan W.;
    • Burge, Russel;
    • Lin, Chen-Yen;
    • Malatestinic, William N.;
    • Goldblum, Orin M.;
    • McLean, Robert R.;
    • Crabtree, Margaux M.;
    • O'Brien, Jacqueline;
    • Grace, Elsie L.;
    • Murage, Mwangi J.
    Publication type:
    Article
    46
    47
    49
    50

    Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials.

    Published in:
    Journal of Dermatological Treatment, 2022, v. 33, n. 3, p. 1521, doi. 10.1080/09546634.2020.1839008
    By:
    • Reich, K.;
    • DeLozier, A. M.;
    • Nunes, F. P.;
    • Thyssen, J. P.;
    • Eichenfield, L. F.;
    • Wollenberg, A.;
    • Ross Terres, J. A.;
    • Watts, S. D.;
    • Chen, Y.-F.;
    • Simpson, E. L.;
    • Silverberg, J. I.
    Publication type:
    Article